ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Trial details
- Registry ID
- NCT06418711
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as MNKD-101
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionNCT06418711 | Mannkind Corporation | Phase 3 | Terminated | 2025-11-10Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |